BIOFIL CHEM & PHARMA Latest Share Price (BIOFILCHEM)
TODAY IN ONE LINE
BIOFILCHEM slumped 6.2% on average volume, lagging Nifty's -0.3% move, with no exchange filing today, suggesting a market-driven move.
With a market cap of ₹55.98 Cr., it trades at a P/E of N/A. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
BIOFIL CHEM & PHARMA flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 10.8% YoY
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.14x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Sales ContractionQuarterly sales dropped 56.5% YoY
- ●Rising Receivables vs SalesReceivables grew 16.0% outpacing sales growth of -16.6%
Latest BIOFIL CHEM & PHARMA News
What changed recently?
Recent events, corporate actions, and announcements.
BIOFIL CHEM & PHARMA valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for BIOFIL CHEM & PHARMA, framed against the sector median so the premium or discount is obvious at a glance.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
BIOFIL CHEM & PHARMA technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for BIOFIL CHEM & PHARMA — derived from the latest tape, not yesterday's close.
BIOFIL CHEM & PHARMA last traded at ₹34.51 with an intraday range of ₹32.36–₹37.8 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹34.51| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 48.30 | +13.79 | +39.96% |
| R3 | 42.86 | +8.35 | +24.20% |
| R2 | 40.33 | +5.82 | +16.86% |
| R1 | 37.42 | +2.91 | +8.43% |
| PIVOT | 34.89 | 0.38 | 1.10% |
| CURRENT | 34.51 | — | — |
| S1 | 31.98 | -2.53 | -7.33% |
| S2 | 29.45 | -5.06 | -14.66% |
| S3 | 26.54 | -7.97 | -23.09% |
| S4 | 21.10 | -13.41 | -38.86% |
BIOFILCHEM is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹32.36–₹37.8
Trading Inside opening range
BIOFIL CHEM & PHARMA financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for BIOFIL CHEM & PHARMA — consolidated or standalone — with margins, YoY growth and key ratios inline.
BIOFIL CHEM & PHARMA reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹55.98 Cr. and reported EPS of ₹0.07.
BIOFIL CHEM & PHARMA segment analysis : revenue and profit mix.
Disclosed business segments at BIOFIL CHEM & PHARMA with their share of revenue and profit, switchable between consolidated and standalone reporting.
BIOFIL CHEM & PHARMA discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for BIOFIL CHEM & PHARMA.
Our AI distills the core fundamental drivers supporting BIOFIL CHEM & PHARMA, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
BIOFIL CHEM & PHARMA's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Near-zero debt-to-equity ratio of 0.0014x provides exceptional financial flexibility.
Latest quarterly EPS grew 6.3% YoY despite revenue headwinds.
TTM EPS grew 10.8% YoY, signaling positive earnings momentum.
P/E of 20.29x trades below peer median, offering valuation comfort.
Diversified pharma-chemicals business with vertical integration in packaging.
Key Risks.
TTM revenue declined 9.3% YoY, reflecting persistent demand weakness.
Operating margin of 1.33% remains critically thin versus peer average.
Operating cash flow negative ₹0.60 Cr (FY26); chronic cash burn despite profits.
Trade receivables ₹27.59 Cr represent 97% of revenue; severe collection risk.
Zero institutional ownership and negligible FII/DII holdings signal low confidence.
Flip Conditions.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
BIOFIL CHEM & PHARMA peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — BIOFIL CHEM & PHARMA is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
BIOFIL CHEM & PHARMA chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for BIOFIL CHEM & PHARMA — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
BIOFIL CHEM & PHARMA delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for BIOFIL CHEM & PHARMA over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in BIOFIL CHEM & PHARMA stood at 59.2% of traded volume, against a 20-day average of 74.7%.
BIOFIL CHEM & PHARMA announcements: results, concalls, ratings, M&A.
Filings BIOFIL CHEM & PHARMA sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
BIOFIL CHEM & PHARMA files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 54 documents below.
Copy of Newspaper Publication
Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication Pursuant to Regulation 30, 44 and 47 of SEBI…
General Updates
Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange about about intimation of e-voting for 41st Annual General Meeting
General Updates
Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange about draft letter to be dispatched to members whose email addresses not…
Shareholders meeting
Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 23, 2026
Copy of Newspaper Publication
Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication of Notice of 41st AGM through Video…
BIOFIL CHEM & PHARMA dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue BIOFIL CHEM & PHARMA has declared, sequenced by announce and record date.
BIOFIL CHEM & PHARMA corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
BIOFIL CHEM & PHARMA insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in BIOFIL CHEM & PHARMA as reported to SEBI — buying and selling signals from the people who know the business best.
BIOFIL CHEM & PHARMA insider activity below tracks 9 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| NIYATI SHAH | Insider | 18 Mar 2026 | buy | +32.7 K | — | — |
| MEENA SHAH | Insider | 18 Mar 2026 | buy | +32.7 K | — | — |
| NIYATI SHAH | Insider | 18 Mar 2026 | buy | +32.7 K | — | — |
| MEENA SHAH | Insider | 18 Mar 2026 | buy | +32.7 K | — | — |
| MEENA SHAH | Insider | 18 Mar 2026 | buy | +32.7 K | — | — |
| NIYATI SHAH | Insider | 18 Mar 2026 | buy | +32.7 K | — | — |
| MEENA SHAH | Insider | 18 Mar 2026 | buy | +32.7 K | — | — |
| NIYATI SHAH | Insider | 18 Mar 2026 | buy | +32.7 K | — | — |
| Niyati Shah | Insider | 06 Jun 2025 | buy | +4.94 L | — | — |
About BIOFIL CHEM & PHARMA: business, sector, key facts.
What BIOFIL CHEM & PHARMA does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
BIOFIL CHEM & PHARMA operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: BIOFILCHEM, BSE: 524396.
Biofil Chemicals and Pharmaceuticals Limited (Biofilchem) is an Indian company primarily engaged in the manufacturing and trading of pharmaceuticals and chemicals. Their business model encompasses two key divisions: Pharmaceuticals and Chemicals. This dual approach allows them to cater to a broader market, encompassing both the production of essential drug components and the finished pharmaceutical products themselves.
The Chemical division focuses on the production and supply of a range of basic drugs and chemical compounds. Their product portfolio includes a variety of inorganic salts crucial in pharmaceutical formulations, such as sodium chloride, potassium chloride, and sodium citrate. They also manufacture organic compounds like diethylcarbamazine citrate, used in anthelmintic medications. In addition to these, Biofilchem produces key excipients, including ferrous sulphate (in both dried and standard forms) and ferrous fumarate, which are frequently used in the manufacture of iron supplements. The company also supplies microcrystalline cellulose, a common pharmaceutical excipient for tablet formulation, and dicyclomine hydrochloride, an antispasmodic agent.
Beyond the core chemical production, Biofilchem also contributes to the packaging side of the pharmaceutical industry. They manufacture plastic drippers and caps, essential components for packaging liquid medications, providing a comprehensive supply chain solution for pharmaceutical companies. This vertical integration strategy strengthens their position within the market and potentially offers improved cost control.
Furthermore, Biofilchem offers job work services, acting as a contract manufacturer for other pharmaceutical companies. This facet of their business involves producing pharmaceutical drugs on behalf of third parties, leveraging their existing manufacturing capabilities to expand their revenue streams and diversify their client base. This service likely contributes to their overall profitability and ensures consistent utilization of their production facilities.
In summary, Biofilchem's business is multifaceted, ranging from the production of essential chemical raw materials and excipients to the manufacturing of finished pharmaceutical products and packaging components. The company's integrated approach, encompassing manufacturing, trading, and contract manufacturing, allows for a diversified and relatively resilient business model within the Indian pharmaceutical market. Established in 1985 and headquartered in Indore, India, Biofilchem has developed a strong foundation within the pharmaceutical and chemical landscape.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Top Losers TodayScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about BIOFIL CHEM & PHARMA (BIOFILCHEM).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of BIOFIL CHEM & PHARMA (BIOFILCHEM)?
The current share price of BIOFIL CHEM & PHARMA (BIOFILCHEM) is ₹34.51. Today, the stock has declined by ₹2.28 (6.2%), trading in a range of ₹32.36 to ₹37.80. The stock opened at ₹37.80 with a trading volume of 1,73,376 shares.
02What is the 52-week high and low price of BIOFIL CHEM & PHARMA stock?
The 52-week high price of BIOFIL CHEM & PHARMA (BIOFILCHEM) is ₹46.34, while the 52-week low is ₹25.60. Currently trading at ₹34.51, the stock is 34.8% above its 52-week low and 25.53% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
03What is the dividend yield of BIOFIL CHEM & PHARMA and when is the next dividend?
BIOFIL CHEM & PHARMA offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹34.51, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
04How is BIOFIL CHEM & PHARMA stock performing today in the market?
BIOFIL CHEM & PHARMA stock opened at ₹37.80 and is currently trading at ₹34.51, showing a decline of ₹2.28 (6.2%). The intraday high is ₹37.80 and low is ₹32.36. The trading volume stands at 1,73,376 shares, indicating moderate market participation today.
05What is the market capitalization of BIOFIL CHEM & PHARMA?
BIOFIL CHEM & PHARMA has a market capitalization of ₹55.98 Cr., making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹34.51) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
06What is the ROE and ROCE of BIOFIL CHEM & PHARMA?
BIOFIL CHEM & PHARMA has a Return on Equity (ROE) of 12.92% and Return on Capital Employed (ROCE) of 11.39%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These are moderate returns, suggesting decent operational efficiency. Higher percentages generally indicate better financial performance.
07Which sector and industry does BIOFIL CHEM & PHARMA belong to?
BIOFIL CHEM & PHARMA operates in the Healthcare sector and belongs to the Pharmaceuticals industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
08What is the debt-to-equity ratio of BIOFIL CHEM & PHARMA?
BIOFIL CHEM & PHARMA has a debt-to-equity ratio of 0.14, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
The data, ratios and commentary about BIOFIL CHEM & PHARMA (BIOFILCHEM) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.